TROG 97.01 - Bladder (Phase II) - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM

TROG 97.01 – Bladder (Phase II)

A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder

TROG 98.01 – Rectal (Phase II)

TROG 96.07 – Merkel Cell – Skin

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM